You could say biotechnology companies' shares were merely "interrupted" this year. Biotech stocks, as measured by the iShares Nasdaq Biotechnology ETF (IBB), started to rally furiously in the back half of 2019. The COVID-sparked market downturn knocked them down, but they've returned to outperformance and are now up 15% year-to-date.
The party likely isn't over, either.
New markets in areas such as anti-aging therapies and gene editing could be worth billions of dollars over the coming decade....
Read this story at Kiplinger